This clinical trial focuses on patients with prostate cancer who have experienced a return of the disease after surgery (known as biochemical recurrence). The study aims to compare two different lengths of treatment using androgen deprivation therapy (a treatment that lowers male hormone levels) combined with salvage radiotherapy (radiation treatment given after surgery).
The study will test three different medications that work to reduce male hormones: Decapeptyl (containing triptorelin), Zoladex (containing goserelin), and Eligard (containing leuprorelin). Some patients will also receive bicalutamide tablets. The medications will be given either as injections under the skin or as tablets to take by mouth. The study compares a short-term treatment lasting 6 months with a longer treatment lasting 24 months.
The main purpose of this research is to determine if using hormone-lowering treatment for a longer time (24 months) leads to better results than shorter treatment (6 months) in preventing the cancer from spreading to other parts of the body. The effectiveness of the treatment will be measured over a 5-year period after starting the therapy.



Spain